147 related articles for article (PubMed ID: 23152403)
1. Cytochrome P450 2B6: function, genetics, and clinical relevance.
Turpeinen M; Zanger UM
Drug Metabol Drug Interact; 2012; 27(4):185-97. PubMed ID: 23152403
[TBL] [Abstract][Full Text] [Related]
2. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Zanger UM; Klein K; Saussele T; Blievernicht J; Hofmann MH; Schwab M
Pharmacogenomics; 2007 Jul; 8(7):743-59. PubMed ID: 17638512
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
Wang H; Tompkins LM
Curr Drug Metab; 2008 Sep; 9(7):598-610. PubMed ID: 18781911
[TBL] [Abstract][Full Text] [Related]
5. [Cyclophosphamide and CYP2B6].
Torimoto Y; Kohgo Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1090-3. PubMed ID: 18633247
[TBL] [Abstract][Full Text] [Related]
6. Equine cytochrome P450 2B6--genomic identification, expression and functional characterization with ketamine.
Peters LM; Demmel S; Pusch G; Buters JT; Thormann W; Zielinski J; Leeb T; Mevissen M; Schmitz A
Toxicol Appl Pharmacol; 2013 Jan; 266(1):101-8. PubMed ID: 23142468
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
8. Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance.
Rohrbacher M; Kirchhof A; Geisslinger G; Lötsch J
Pharmacogenomics; 2006 Oct; 7(7):995-1002. PubMed ID: 17054410
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
10. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.
Xie HJ; Yasar U; Lundgren S; Griskevicius L; Terelius Y; Hassan M; Rane A
Pharmacogenomics J; 2003; 3(1):53-61. PubMed ID: 12629583
[TBL] [Abstract][Full Text] [Related]
11. Role of CYP2B6 in stereoselective human methadone metabolism.
Totah RA; Sheffels P; Roberts T; Whittington D; Thummel K; Kharasch ED
Anesthesiology; 2008 Mar; 108(3):363-74. PubMed ID: 18292673
[TBL] [Abstract][Full Text] [Related]
12. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
13. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
Bumpus NN; Sridar C; Kent UM; Hollenberg PF
Drug Metab Dispos; 2005 Jun; 33(6):795-802. PubMed ID: 15769884
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).
Watanabe T; Sakuyama K; Sasaki T; Ishii Y; Ishikawa M; Hirasawa N; Hiratsuka M
Pharmacogenet Genomics; 2010 Jul; 20(7):459-62. PubMed ID: 20517174
[TBL] [Abstract][Full Text] [Related]
15. Novel CYP2B6 enzyme variants in a Rwandese population: functional characterization and assessment of in silico prediction tools.
Radloff R; Gras A; Zanger UM; Masquelier C; Arumugam K; Karasi JC; Arendt V; Seguin-Devaux C; Klein K
Hum Mutat; 2013 May; 34(5):725-34. PubMed ID: 23418033
[TBL] [Abstract][Full Text] [Related]
16. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
Talakad JC; Kumar S; Halpert JR
Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
[TBL] [Abstract][Full Text] [Related]
17. Haplotype structure and allele frequencies of CYP2B6 in a Korean population.
Cho JY; Lim HS; Chung JY; Yu KS; Kim JR; Shin SG; Jang IJ
Drug Metab Dispos; 2004 Dec; 32(12):1341-4. PubMed ID: 15383491
[TBL] [Abstract][Full Text] [Related]
18. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
19. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.
Bumpus NN; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2006 Jul; 318(1):345-51. PubMed ID: 16611850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
